TAVOTEK

Tavotek Biotherapeutics to Attend 2022 San Antonio Breast Cancer Symposium

 发布时间 : 2022-12-06  点击量 : 3549

(LOWER GWYNEDD, Pennsylvania, December 6, 2022) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, will attend the 2022 San Antonio Breast Cancer Symposium located in San Antonio, TX. Tavotek will showcase TAVO412, a novel multispecific antibody with unique 2:1:1 ratio of EGFR:cMet:VEGF binding arms with excellent activity against TNBC. About TavotekTavotek Biotherapeutics is a multi-speci....

Tavotek Biotherapeutics Doses First Patient in Phase 1 First-in-Human Clinical Trial of TAVO412, a Multispecific Biologic for Solid Tumors

 发布时间 : 2023-05-09  点击量 : 6651

Tavotek Biotherapeutics Doses First Subject in Phase 1 First-in-Human Clinical Trial of TAVO412, a Multispecific Biologic for Solid TumorsMay 9, 2023 at 8:00 AM ESTLower Gwynedd, Pennsylvania – May 9th, 2023 – Tavotek Biotherapeutics announced today that its multispecific antibody, TAVO412, has been successfully dosed in its first patient at Mount Sinai Hospital in New York City, NY. TAVO412 is a first-in-class multispecific antibody developed for patients with solid tumors. This study, termed T....

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania

 发布时间 : 2023-03-15  点击量 : 4703

(LOWER GWYNEDD, Pennsylvania, March 15, 2023) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, was named a finalist for the 2022 Emerging Company of the Year Award by Life Sciences Pennsylvania.The Emerging Company of the Year Award recognizes a company or organization that has experienced significant growth and/or achievement in 2022, while contributing positively to its community and t....

Tavotek Biotherapeutics Attends The 41st Annual J.P. Morgan Healthcare Conference

 发布时间 : 2023-01-09  点击量 : 5386

(LOWER GWYNEDD, Pennsylvania, January 9, 2023) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, attended the 41st annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California. Dr. Mann Fung, MD, CEO of Tavotek, and Dr. Mark Chiu, PhD, CSO of Tavotek, met and connected with top industry leaders, innovative biotech startups, cutting-edge techn....

Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412

 发布时间 : 2022-10-28  点击量 : 6053

(LOWER GWYNEDD, Pennsylvania, October 28, 2022) Tavotek Biotherapeutics announced today that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a two-part Phase 1, first-in-human (FIH), clinical study of TAVO412 for the treatment of advanced or metastatic solid tumors. TAVO412 is a novel multi-specific antibody targeting cMET, EGFR, and VEGF and was created and engineered by using the company’s proprietary Tavo....

Tavotek Pivotal Asset Tavo412 Presented at 2022 AAPS National Biotech Conference

 发布时间 : 2022-05-12  点击量 : 3796

(LOWER GWYNEDD, Pennsylvania, May 12, 2022) Tavotek Biotherapeutics, a fast-growing biopharmaceutical company, announced that its pivotal oncology asset Tavo412 was presented today at the 2022 AAPS National Biotechnology Conference in Anaheim, California. American Association of Pharmaceutical Scientists (AAPS) is an association with nearly 9,000 scientists interested in advancing the development of therapies to address global medical needs. The AAPS National Biotechnology Conference is a pre....

Tavotek Biotherapeutics Announces Formation and Member of Scientific Advisory Board

 发布时间 : 2022-04-25  点击量 : 3775

(LOWER GWYNEDD, Pennsylvania, April 25, 2022) Tavotek Biotherapeutics, a fast-growing biopharmaceutical company focusing on discovering and developing therapeutic medicines, announced the formation of a Scientific Advisory Board (SAB) comprised of scientific and industry leaders in oncology and immunology. The SAB will work cohesively with Tavotek to advance the company’s discovery and clinical pipelines“The distinguished group of industry experts and scientific leaders that we have assembled w....

Tavotek Launching First-In-Human Study of Two Assets In 2022

 发布时间 : 2022-04-07  点击量 : 4191

(LOWER GWYNEDD, Pennsylvania, April 5, 2022) Tavotek Biotherapeutics announced today that its first pipeline biologic asset, TAVO103A, had been successfully dosed in two human subjects in the ICON Phase 1 Clinical Trial Center in Salt Lake City, Utah. TAVO103A is a best-in-class human monoclonal antibody developed for chronic inflammation. This study, termed TAVO103A-0001, is a double-blind, randomized, placebo-controlled Phase 1 evaluation of the safety, tolerability, immunogenicity, and PK/....

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

 发布时间 : 2021-11-18  点击量 : 3352

LOWER GWYNEDD, Penn., Nov. 18, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody pla....

Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents

 发布时间 : 2021-08-17  点击量 : 3568

CHEYNEY, Pa. and AMBLER, Pa., Aug. 17, 2021 /PRNewswire/ -- Navrogen Inc. ("Navrogen"), a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics ("Tavotek"), a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of var....

Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars

 发布时间 : 2021-03-22  点击量 : 3568

LOWER GWYNEDD, Pennsylvania, March 22, 2021 /PRNewswire/ -- Tavotek Biotherapeutics announces it has raised over $20M in Round A1 and Round A2 financing in the preceding two months. YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital. Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital. The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody dru....

Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets

 发布时间 : 2020-05-25  点击量 : 3330

AMBLER, Pa., May 25, 2020 /PRNewswire/ -- Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens. Tavotek employs TavoSelect™, with proprietary VHO phage and Fab phage libraries, to efficiently identify lead molecules for gener....

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

 发布时间 : 2020-01-06  点击量 : 3344

GAITHERSBURG, Md. and AMBLER, Pa., Jan. 6, 2020 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that the companies have entered into a strategic research alliance and collaborate in the devel....